Boston Scientific (BSX) Reports In-Line Q1 EPS

Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.39, in-line with the analyst estimate of $0.39. Revenue for the quarter came in at $3.03 billion versus the consensus estimate of $2.95 billion.

GUIDANCE:

Boston Scientific sees Q2 2022 EPS of $0.41-$0.43. Boston Scientific sees Q2 2022 revenue of $0.44 billion. The company estimates net sales growth for the second quarter of 2022, versus the prior year period, to be in a range of approximately 3 to 6 percent on a reported basis and organic basis.

Boston Scientific sees FY2022 EPS of $1.74-$1.79. Boston Scientific sees FY2022 revenue of $1.77 billion. The company now estimates net sales growth for the full year 2022, versus the prior year period, to be in a range of approximately 7 to 9 percent on a reported basis, and approximately 6.5 to 8.5 percent on an organic basis.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating